Quinidine; Natisedine/Selected QT Prolongers
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Quinidine, which is also a component of natisedine, may affect your heart's rhythm. Other drugs can have the same effect.
What might happen:
Taking quinidine or natisedine with agents that can affect your heart rhythm may increase your risk of an irregular heartbeat, which may be life-threatening.
What you should do about this interaction:
Let your healthcare professionals (e.g doctor or pharmacist) know right away that you are taking these medications together. Let your doctor know right away if you notice an irregular heartbeat or have dizziness or fainting episodes.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
2.Firdapse (amifampridine phosphate) UK summary of product characteristics. BioMarin Europe Limited February, 2010.
3.Riamet (artemether/lumefantrine) UK summary of product characteristics. Novartis Pharmaceuticals UK Ltd. June 27, 2001.
4.Fareston (toremifene citrate) UK summary of product characteristics. Orion Pharma (UK) Limited January, 2009.
5.Vascor (bepridil hydrochloride) US prescribing information. Ortho-McNeil Pharmaceutical, Inc. March, 2000.
6.Multaq (dronedarone) US prescribing information. Sanofi-Aventis U.S. LLC January, 2014.
7.Orlaam (levomethadyl acetate hydrochloride) US prescribing information. Roxane Laboratories, Inc. May, 2001.
8.Agrylin (anagrelide hydrochloride) US prescribing information. Shire US Inc. February, 2014.
9.Inapsine (droperidol) US prescribing information. Akorn, Inc. November, 2001.
10.Coartem (artemether/lumefantrine) US prescribing information. Novartis Pharmaceuticals Corporation April, 2013.
11.The University of Arizona Center for Education and Research of Therapeutics. Drugs with Risk of Torsades de Pointes and Drugs with Possible Risk of Torsades de Pointes. Available at:http://www.crediblemeds.org/. Updated March 14, 2013.
12.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.